Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07611201 · ClinicalTrials.gov registry record
The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior
A clinical trial, sponsored by Purdue University.
- Completed
- Registry status
- 90
- Enrollment target
NCT07611201: Completed study, sponsored by Purdue University.
NCT07611201 is a clinical trial that has completed, run by Purdue University. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07611201 has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
The goal of this study is to explore whether of GLP-1 receptor agonist use is associated with differences in taste, smell, food preferences, appetite, food cravings, and responses to food cues in adults. The study includes adults who are not currently taking a GLP-1 receptor agonist but may be eligible to use one, and adults who are already taking a GLP-1 receptor agonist as part of their regular medical care for approximately 1 month or approximately 6 months. The main questions it aims to answer are: Are taste and smell function different among adults who are not taking a GLP-1 receptor agonist and adults who have been taking one for different lengths of time? Are food preferences, appetite, food cravings, food reward, attention to food cues, and salivary responses to food cues different among these groups? Researchers will compare adults not currently taking a GLP-1 receptor agonist with adults taking a GLP-1 receptor agonist for approximately 1 month or approximately 6 months. The research team will not prescribe, assign, or provide GLP-1 receptor agonist medications. People in the study will attend two in-person study visits, complete taste and smell tests, complete food preference and computer-based tasks, and provide saliva samples during a food cue task. Questionnaires about appetite, cravings, food cues, and eating behavior will be completed at home over approximately 2 weeks.
Primary Outcome
Taste detection thresholds will be assessed for sweet, salty, sour, and bitter stimuli (sucrose, sodium chloride, citric acid, and urea, respectively) using a two-alternative forced-choice staircase procedure, in which participants identify which of two samples contains the taste stimulus. Separate outcomes will be reported for each taste quality: sweet, salty, sour, and bitter. For each taste quality, the threshold will be calculated as the geometric mean concentration at which the stimulus is
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-02-20 |
| Est. Completion | 2026-05-04 |
What the finished NCT07611201 record still lists
NCT07611201 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07611201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07611201 about?
NCT07611201 is a clinical study titled "The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior". The goal of this study is to explore whether of GLP-1 receptor agonist use is associated with differences in taste, smell, food preferences, appetite, food cravings, and responses to food cues in adults. The study includes adults who are not currently taking a GLP-1 receptor agonist but may be eligi...
What is the current status of trial NCT07611201?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2025-02-20. Estimated completion is 2026-05-04.
Who is sponsoring clinical trial NCT07611201?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI